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BACKGROUND
Alzheimer’s Disease (AD) is currently conceived as a continuum that can be 
characterized by performing combined assays, including neuropathological 
findings and AD-specific biomarkers - CSF (t-Tau, p-Tau, Aβ42) and neuroimaging 
biomarkers (MRI, FDG-PET, Aß-PET). However, invasiveness, high cost, and 
insufficient availability of current biomarkers limit their use in routine 
clinical practice for AD diagnosis, therefore a refocusing towards the 
identification of blood-based biomarkers has been proposed. [1]
Moreover, due to high stability in biofluids and easy quantification, the 
identification of altered miRNA expression profiles in AD patients represents 
a promising approach for developing novel AD-specific blood-based biomarkers.
 
Within this research proposal, the analysis of synaptic miRNAs is suggested as 
a potential AD-biomarker, since synaptic impairment has been recently 
identified as an upstream event in AD pathology, which precedes neuronal loss. 
This project aims to propose and experimentally validate a novel plasma miRNA 
signature that accurately distinguishes between the different stages of AD, and 
therefore that could serve as a reliable biomarker for the detection of AD 
during its early stages.
HYPOTHESIS AND OBJECTIVES 
Alterations in the plasma expression profile of proposed miRNAs can be useful as 
a reliable non-invasive AD-specific biomarker for an early-diagnosis of AD
To evaluate the diagnostic capacity of proposed miRNAs in plasma as potential 
AD-biomarkers, and estimate their disease specificity versus other 
neurodegenerative diseases.
To determine whether variations in the plasma expression profile of these 
miRNAs provide an insight into AD’s pathological changes in the brain tissue. 
To examine whether these miRNAs present a similar expression pattern in both 
plasma and CSF. 
PROJECT DEVELOPMENT
For the project development, a bibliographic research has been conducted on miRNAs 
involved in normal synaptic function, and its analysis in clinical samples:
The most used databases were PubMed, and MiRBase.
Research key words: “AD blood-based biomarkers”, ”miRNAs in AD”, “miRNAs and 
synaptic function”, “miRNA-guided diagnosis”.
SYNAPTIC miRNAs PROPOSAL
Figure 1: Overview of proposed miRNAs  at the synaptic compartment.
Abbreviations: SYN2, Synapsin 2; SNAP25, Synaptosomal-associated protein 25; SYT1,  
synaptotagmin 1; STX1, syntaxin 1; SV2A, Synapse vesicle 2A; SYB, Synaptobrevin; 
Arp2/3, Actin-related protein 2/3. [2]
STUDY DESIGN AND DEVELOPMENT PLAN 
Figure 2: An internationally two-stage cross-sectional study.
600 individuals will be recruited from hospitals in countries with a high incidence 
of AD, and distributed into the following groups according to the inclusion criteria; 
healthy controls (HC), mild cognitive impairment due to AD (MCI), Alzheimer's Disease 
(AD), and Parkinson’s Disease (PD).
Figure 3: Project timeline.
Scheme representing the project work-flow through a four-year development plan, and 
outlining the study design into two different stages: stage 1 or pilot study and 
stage 2 or validation study.
EXPERIMENTAL PROCEDURES AND EXPECTED RESULTS 
Figure 4: Sample collection and Handling.
Specimens will be collected and processed 
following the preanalytical standard 
operating procedures of BIOMARKAPD 
consortium.
Figure 5: RNA extraction.
It will be performed using miRNeasy 
Serum/Plasma Advanced Kit (Qiagen). C.elegans 
miRNA cel-miR-39 (Qiagen) will be used as 
an internal reference for normalization. [3]
Figure 6: Measurement of miRNAs levels by RT-qPCR 
assays.
Purified miRNA will be reversed transcribed to 
cDNA using TaqMan miRNA Reverse Transcription Kit 
(Applied Biosystems) and amplified by qPCR. [3]
Figure 7: miRNA signature validation.
ROC curve assays will be performed for the 
evaluation of miRNA diagnostic capacity. 
This image shows an example of a ROC curve 
analysis for selected miRNA in MCI.
CONCLUSIONS
Nowadays, to establish an early diagnosis of AD is essential to advance in its therapeutic approach for 
several reasons:
To increment the effectiveness of available treatments.
 
To allow individuals to establish their health-care programs and decide about important matters before 
becoming demented. 
To provide time to perform multiple interventions for the early prevention of cognitive decline. 
Therefore, this research proposal represents the first step in the development of a consistent, non-invasive 
biomarker that could assist in the routine clinical practice for AD diagnosis in its early stage.
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